Q2 2024 · 13F-HR
Fairmount Funds Management LLCholdings as filed
Filed 2024-08-14 · accession 0001104659-24-089572
$885.1M
Reported value
13
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $190.0M | 21.5% | 2,360,077 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $146.0M | 16.5% | 1,924,626 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $94.5M | 10.7% | 4,018,101 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $80.6M | 9.11% | 2,048,647 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $74.8M | 8.46% | 3,202,798 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $71.5M | 8.08% | 2,762,837 | Common | SOLE |
| G52694109 | KNSA | KINIKSA PHARMACEUTICALS INTL | $59.8M | 6.76% | 3,204,841 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $52.5M | 5.93% | 6,225,641 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $32.3M | 3.65% | 3,554,129 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $32.3M | 3.65% | 931,890 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $24.0M | 2.71% | 1,845,813 | Common | SOLE |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC | $21.6M | 2.44% | 1,069,199 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $5.1M | 0.58% | 748,996 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.